|
Patent landscape, scope, and claims: |
Analysis of U.S. Drug Patent 8,591,941
U.S. Patent 8,591,941, titled "Cyclopropyl-Containing Pyridazine Derivatives as PDE10 Inhibitors," was granted to Pfizer Inc. on December 10, 2013. The patent claims a class of novel compounds and their use in treating central nervous system (CNS) disorders. The core of the patent lies in its specific chemical structures and their demonstrated inhibitory activity against phosphodiesterase 10A (PDE10A), a key enzyme implicated in neurological and psychiatric conditions.
What Does Patent 8,591,941 Claim?
What are the core chemical structures protected by the patent?
The patent protects a genus of cyclopropyl-containing pyridazine derivatives defined by a specific Markush structure. This structure encompasses a range of substituents that allow for variation while maintaining the core pharmacophore responsible for PDE10A inhibition.
- Generic Formula: The patent defines a generic formula (I) which includes:
- A pyridazine ring substituted at specific positions.
- A cyclopropyl group attached to the pyridazine core or a linker.
- Various aromatic or heteroaromatic rings and aliphatic substituents attached at defined positions on the pyridazine core.
- Specific ranges for the allowed atoms and groups (R1, R2, R3, R4, etc.) are enumerated, detailing the scope of chemical diversity.
What is the claimed mechanism of action?
The compounds described in Patent 8,591,941 are claimed to act as inhibitors of phosphodiesterase 10A (PDE10A).
- PDE10A's Role: PDE10A is an enzyme primarily expressed in the striatum of the brain. It regulates intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), which are crucial second messengers involved in neuronal signaling and plasticity.
- Inhibition Mechanism: By inhibiting PDE10A, the claimed compounds increase cAMP and cGMP levels in striatal neurons. This modulation is hypothesized to restore normal neurotransmission and neuronal function.
What therapeutic uses are covered by the patent?
The patent broadly claims the use of these PDE10A inhibitors for the treatment of various CNS disorders.
- Targeted Conditions: The patent explicitly lists conditions such as:
- Schizophrenia
- Bipolar disorder
- Depression
- Anxiety disorders
- Parkinson's disease
- Huntington's disease
- Alzheimer's disease
- Other neurological and psychiatric conditions characterized by aberrant striatal function.
- Dosage and Administration: The patent also describes methods of administration and effective dosage ranges for these therapeutic applications.
What is the Patent Landscape for PDE10A Inhibitors?
Who are the key players in PDE10A inhibitor patenting?
Pfizer Inc. is a prominent patent holder in the PDE10A inhibitor space, with Patent 8,591,941 representing a significant portion of its intellectual property in this area. Other pharmaceutical companies and research institutions have also filed patents related to PDE10A inhibitors, creating a complex landscape.
- Major Assignees: Key assignees in PDE10A inhibitor patenting include:
- Pfizer Inc.
- Novartis AG
- Merck & Co., Inc.
- Takeda Pharmaceutical Company Limited
- Sanofi-Aventis
- Eli Lilly and Company
- Various academic institutions.
How does Patent 8,591,941 compare to other PDE10A inhibitor patents?
Patent 8,591,941 is characterized by its specific focus on cyclopropyl-containing pyridazine derivatives. This distinguishes it from patents claiming different chemical scaffolds or targeting different enzyme families.
- Structural Differentiation:
- While other patents may claim broader classes of compounds or different heterocyclic cores (e.g., pyrazoles, indoles), Patent 8,591,941's claims are narrowly tailored to a specific chemical motif.
- The inclusion of the cyclopropyl group is a defining feature, potentially conferring specific pharmacokinetic or pharmacodynamic properties.
- Therapeutic Overlap: Many patents in the PDE10A inhibitor space target similar CNS disorders, leading to potential overlap in claimed therapeutic uses.
What is the patent expiration timeline for this class of compounds?
The expiration of Patent 8,591,941 will significantly impact market exclusivity for any drugs developed and approved based on its claims.
- U.S. Patent 8,591,941:
- Grant Date: December 10, 2013
- Original Expiration Date: May 30, 2026 (20 years from the filing date of August 10, 2006, minus any patent term extensions)
- Potential for Extension: Patent term extension (PTE) may have been sought and granted, potentially extending the patent's life for a period equivalent to a portion of the FDA regulatory review.
- Related Applications and Foreign Patents: A comprehensive analysis would also consider the expiration dates of any related U.S. continuation or divisional applications, as well as corresponding patents filed in other jurisdictions, which may have different expiration dates.
What is the Commercial and R&D Significance?
What is the current R&D focus around PDE10A inhibitors?
Despite the maturity of the patent landscape, R&D in PDE10A inhibitors continues, driven by the unmet medical needs in CNS disorders.
- Clinical Stage Compounds: Several PDE10A inhibitors are in various stages of clinical development for conditions like schizophrenia and Huntington's disease. Examples include compounds from Pfizer, Novartis, and Merck.
- New Chemical Entities: Research is ongoing to identify novel PDE10A inhibitors with improved efficacy, safety profiles, and pharmacokinetic properties, potentially exploring new chemical scaffolds or allosteric modulators.
- Biomarker Development: Efforts are also underway to identify biomarkers that can predict patient response to PDE10A inhibitors, aiding in patient stratification and clinical trial design.
What are the implications of Patent 8,591,941's expiration?
The expiration of Patent 8,591,941 will allow for generic competition and potentially lower drug prices for therapies based on its claims.
- Generic Entry: Following patent expiration, generic manufacturers can seek approval to market bioequivalent versions of approved drugs, provided they do not infringe on other valid patents (e.g., formulation patents, method of use patents).
- Market Dynamics: Generic entry typically leads to a significant decrease in the market share and price of the branded drug.
- Impact on Pfizer: For Pfizer, the expiration represents a loss of market exclusivity for any products covered by this patent, necessitating a focus on pipeline assets or new intellectual property.
What is the investment perspective on PDE10A inhibitors?
Investment in PDE10A inhibitors is contingent on several factors, including the stage of development of a company's assets, the strength of its intellectual property portfolio, and the projected market for specific CNS indications.
- Risk Factors:
- Clinical Trial Failure: High attrition rates in CNS drug development.
- Regulatory Hurdles: Stringent FDA approval processes for CNS drugs.
- Competitive Landscape: Presence of other therapeutic modalities and existing treatments.
- Patent Cliff: Expiration of key patents creating opportunities for generic competition.
- Opportunities:
- Unmet Medical Need: Significant demand for effective treatments for debilitating CNS disorders.
- First-in-Class Potential: Novel mechanisms of action can offer advantages over existing therapies.
- Strategic Partnerships: Collaborations with established pharmaceutical companies can de-risk development.
Patent Claims Analysis
Patent 8,591,941 contains a series of claims directed to the compounds, compositions, and methods of use.
Claim 1: Compound Definition
Claim 1 is the broadest independent claim and defines the core chemical structure.
Dependent Claims: Narrowing the Scope
Dependent claims build upon the independent claims by adding further limitations, thereby narrowing the scope of protection.
- Examples of Limitations:
- Specific Substituents: Claims specifying particular groups for R1, R2, R3, or R4. For example, a claim might be directed to compounds where R1 is a particular substituted phenyl ring.
- Stereochemistry: Claims may define specific enantiomers or diastereomers if stereochemistry is critical to activity.
- Salt Forms: Claims can cover specific pharmaceutically acceptable salts of the claimed compounds.
- Purpose: These claims provide layered protection, ensuring coverage even if broader claims are challenged. They also define specific compounds that may have been synthesized and tested extensively.
Composition Claims
These claims cover pharmaceutical compositions containing the active compounds.
- Key Elements:
- Active Ingredient: One or more compounds of formula (I) or a pharmaceutically acceptable salt thereof.
- Excipients: Pharmaceutically acceptable carriers, diluents, binders, disintegrants, lubricants, etc.
- Scope: Covers various dosage forms, such as tablets, capsules, solutions, and suspensions.
Method of Use Claims
These claims protect the therapeutic applications of the claimed compounds.
- Core Claim: A method of treating a CNS disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
- Specific Disorders: Dependent claims often list the specific disorders for which the method is claimed, aligning with the therapeutic uses discussed earlier (e.g., schizophrenia, depression).
- Dosage and Administration: Claims can also specify dosage ranges or routes of administration.
Conclusion
U.S. Patent 8,591,941 represents a significant intellectual property asset for Pfizer Inc., protecting a specific class of cyclopropyl-containing pyridazine derivatives as PDE10A inhibitors. The patent's strength lies in its detailed definition of chemical structures and their claimed utility in treating a range of debilitating CNS disorders. As the patent approaches its expiration date, understanding its scope and the broader competitive landscape is crucial for strategic R&D planning and investment decisions in the highly competitive CNS therapeutic area.
Key Takeaways
- U.S. Patent 8,591,941 protects cyclopropyl-containing pyridazine derivatives acting as PDE10A inhibitors.
- The patent claims specific chemical structures, pharmaceutical compositions, and methods for treating CNS disorders including schizophrenia and depression.
- Pfizer Inc. is the assignee. The original expiration date is May 30, 2026, subject to potential Patent Term Extension.
- The PDE10A inhibitor landscape is competitive, with multiple companies pursuing this target, necessitating careful analysis of overlapping intellectual property.
- Patent expiration will open the door for generic competition, significantly altering market dynamics for any approved therapeutics based on its claims.
Frequently Asked Questions
-
What is the primary target of the compounds claimed in U.S. Patent 8,591,941?
The primary target is phosphodiesterase 10A (PDE10A).
-
Which specific CNS disorders are covered by the therapeutic use claims in this patent?
The patent covers disorders such as schizophrenia, bipolar disorder, depression, anxiety disorders, Parkinson's disease, Huntington's disease, and Alzheimer's disease.
-
When is the expected expiration date for U.S. Patent 8,591,941?
The original expiration date is May 30, 2026, though this could be extended by Patent Term Extension.
-
Besides Pfizer Inc., which other entities are notable in the PDE10A inhibitor patent landscape?
Key players include Novartis AG, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, and Sanofi-Aventis.
-
Does this patent cover specific drugs that are currently on the market?
A thorough analysis would be required to determine if any currently marketed drugs fall directly under the claims of this specific patent. Patent 8,591,941 describes a genus of compounds, and specific drugs may be covered by narrower patents or patents on specific salt forms or formulations.
Citations
[1] Pfizer Inc. (2013). Cyclopropyl-Containing Pyridazine Derivatives as PDE10 Inhibitors (U.S. Patent No. 8,591,941). Washington, D.C.: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
